Table 2.

Factors associated with acute care use among patients after initiation of androgen receptor signaling inhibitors

Covariates	Incidence Rate Ratio (95% CI)	p-value
Diabetes (Yes vs No)	1.38 (1.11–1.70)	0.003**
Drug type (Abi vs Enza/Apa)	1.43 (1.12–1.82)	0.005*
Age (per year)	1.01 (1.00 −1.02)	0.18
NCI comorbidity index (per unit)	1.49 (1.24–1.80)	<0.001**
Race (Black vs White)	1.01 (0.75–1.36)	0.95
Race (Other vs White)	1.32 (0.91–1.92)	0.15
Marital Status (Unmarried vs Married)	1.25 (1.02–1.53)	0.03*
Region (Northern Plains vs East)	0.93 (0.69–1.24)	0.61
Region (Pacific Coast vs East)	0.88 (0.71–1.09)	0.23
Region (Southwest vs East)	1.11 (0.73–1.60)	0.62
SES (Non HS >10% vs <10%)	0.92 (0.76–1.11)	0.39

^*P<0.05,

^**P<0.01